PONVORY® (ponesimod)
Relapsing forms of Multiple Sclerosis
Key Facts
About Juvise Pharmaceuticals
Juvise Pharmaceuticals is a private, commercial-stage specialty pharma company with a unique business model centered on acquiring mature, essential medicines from larger pharmaceutical firms. It operates internationally, with a strong European manufacturing base, and focuses on therapeutic areas including Multiple Sclerosis, Gastroenterology, Oncology, Cardiology, Rheumatology, and Neuropsychiatry. The company recently expanded its portfolio and capital base by acquiring global rights (ex-US/Canada) to PONVORY® and securing investment from Bpifrance and Pemberton, signaling a phase of strategic growth.
View full company profileAbout Vanda Pharmaceuticals
Vanda Pharmaceuticals is a publicly traded biopharma company with a mission to 'innovate in the service of people's pursuit of happiness' by developing targeted therapies for CNS and sleep disorders. Its core strategy integrates genetics and genomics into all stages of drug development to enhance clinical trial success and commercial positioning. Key achievements include the FDA approvals of Fanapt® for schizophrenia and Hetlioz® for Non-24, with recent milestones including the 2026 approval of BYSANTI™ and a landmark FDA hearing for Hetlioz® in Jet Lag Disorder.
View full company profileTherapeutic Areas
Other Relapsing forms of Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| BRIUMVI (ublituximab) | TG Therapeutics | Approved |